Several clinical studies in HCV-induced vasculitis [78], GvHD [79], and type 1 diabetes have reported that low dose IL-2 therapy is safe, expands Treg frequency, and improves their functional capacity [80, 81]. The gene discussed is IL2; the disease is vasculitis.